Purpos e: The aim of this study was to dete rmine the prognos tic factors and treatme nt outcome of fo r e lderly patients (age 60 at time of diag nos is ) w ith aggres s ive no n-Hodg kin's lymphoma (NHL).
INTRODUCTION
Combination chemotherapy for aggressive non-Hodgkin's lymphoma (NHL) has changed the prognosis of this disease and has often led to long-term remission. However, elderly patients are often excluded from this therapy for a variety of reasons including poor performance, poor compliance, expected significant toxicity or associated underlying diseases. Many of these patients are instead treated with an arbitrarily adjusted suboptimal dose and/or schedule of chemotherapy. Although approximately 55% of all aggressive NHL are diagnosed in patients older than 60 years of age and age has been shown to be the most important prognostic factor independently associated with poor survival in patients with NHL, some elderly patients can achieve long-term remission by combination chemotherapy (1) . As the numbers of elderly patients suffering from NHL are increasing, and all patients with a possible good prognosis should be treated aggressively, it is very important to discriminate these patients from other elderly NHL patients. This study was undertaken in order to determine the prognostic factors and treatment outcome in elderly patients with aggressive NHL.
MATERIALS AND METHODS

1) Patients
Between January 1990 and May 2000, 52 patients aged 60 or older were diagnosed with aggressive NHL (by REAL classification) on the basis of histologic findings at Hanyang University Hospital. The medical records of these fifty-two patients were retrospectively reviewed. The clinical features evaluated for potential prognostic value were age, sex, tumor stage, performance status, number of extranodal disease, B symptom, serum level of LDH, hemoglobin (Hb), albumin, chemotherapeutic regimen, and clinical response to treatment. In all cases, staging was performed according to the criteria of the Ann Arbor system and the histological subgroups were classified according to REAL classification.
2) Treatment regimens
Forty-nine of the 52 patients received combination chemotherapy. Twenty-two patients were administered CHOP (cyclophosphamide 750 mg/m 2 iv D1, adriamycin 50 mg/m 2 iv D1, vincristine 1.4 mg/m 2 iv D1, and prednisone 100 mg po D1-5) and ten patients were treated with proMACE-cytaBOM (cyclophosphamide 650 mg/m 2 iv D1, doxorubicin 25 mg/m 2 iv D1, etoposide 120 mg/m 2 iv D1, prednisone 60 mg/m 2 po D1-14, cytarabine 300 mg/m 2 iv D8, vincristine 1.4 mg/m 2 iv D8, bleomycin 5 U/m 2 iv D8, and methotrexate 120 mg/m 2 iv D8). The remaining patients were treated with various other regimens; MACOP-B, M-BACOD, CAP, Bleo-CHOP, MINE, or VP. A total of 216 courses of chemotherapy were given (median 5 courses). Seven patients received radiotherapy and the average dose was 41.9 Gy. Three patients were treated with conservative therapy due to the following reasons: two patients refused treatment and the other developed panperitonitis. These three patients were excluded from our analysis of survival and prognostic factors.
3) Response
Complete remission (CR) was defined as the absence of clinically detectable disease and partial remission (PR) as a decrease of more than 50% of tumor volume (sum of the products of maximal perpendicular diameters) for at least 4 weeks. Progressive disease was defined as an increase of at least 25% in the overall area of the tumor or the appearance of new lesions. Other outcomes were considered stable disease. Overall survival was measured from the date of diagnosis to the time of death or last follow-up.
4) Statistical analysis
Statistical analysis was performed using chi-square tests to compare percentages in cross tabulations. Survivals were calculated according to the Kaplan-Meier method and compared with the log-rank test. Prognostic factors for survival were identified by a Cox-regression analysis. A P value of less than 0.05 was considered significant.
RESULTS
1) Patient characteristics
The median age was 69 years (range: 60 92) and 25 patients were older than 70 years. Thirty-two were male. The median performance status was ECOG 1 (range: 1 3). The histologic findings by REAL classification included diffuse large B cell (53.8%), peripheral T cell (23.1%), AILD-like T-cell (3.8%), angiocentric (3.8%), mantle cell (3.8%), Burkitt's lymphoma (3.8%), and others (7.9%). According to the Ann Arbor staging system, 19 (37.3%) patients were stage I and II and 32 (62.7%) patients were III and IV. Six (11.5%) patients had 2 or more extranodal diseases and 31 (60.8%) had elevated LDH level. By an international prognostic index that was composed of age at diagnosis, performance status, serum LDH level, Ann Arbor stage, and number of extranodal disease, 15 (28.8%) patients were low, 11 (21.2%) patients were low intermediate, 9 (17.3%) were high intermediate, and 17 (32.7%) were high-risk group (Table 1) .
2) Treatment response and survival duration
Among the forty-nine patients treated with chemotherapy, 28 (57.1%) patients achieved CR, 8 (16.3%) patients PR, and the remaining 13 (26.5%) patients failed to respond to the therapy. The achievement of CR was not associated with age, sex, performance status, stage, IPI, LDH, WBC count, Hb, or B symptom. Because the intensity of administered dose of each cycle could not be calculated, the influence of dose-intensity to achievement of CR was not estimated. The median follow-up for surviving patients in this study was 26.6 months (range: 5.3 117.6 months). The overall median survival for those patients treated with combination chemotherapy was 22.7 months (range: 1.1 117.6 months) and the 2-year survival rate (Fig. 1) . The median survival for patients who achieved CR was 52.6 months and 5.1 months for patients who had PR or failed to respond, a significant difference (P 0.001, Fig. 1 ).
3) Toxicity
Grade 3 or 4 hematologic toxicity was observed in 18 patients (36.7%). Neutropenia occurred in 36.7% of patients, anemia in 14.3% and thrombocytopenia in 6.1%. Other significant adverse events included pneumonia (3 patients), sepsis (2 patients), mucormycosis (1 patient), and cardiomyopathy (1 patient). Twenty-nine of the 52 patients died during follow-up. The causes of death included progression of the disease (21 patients), sepsis (6 patients), panperitonitis (1 patient), and cardiomyopathy (1 patient).
4) Prognostic factors
The eight good prognostic factors for overall survival identified by our univariate analysis included age 70 years (P=0.04, Fig. 2 ), low and low intermediate IPI (P=0.02), good performance (P=0.04), normal WBC (P=0.008), normal Hb (P=0.02), normal LDH (P=0.04), CR on first line therapy (P 0.001), and absence of B symptom (P=0.001, Table 2 ). In the multivariate analysis, the independently significant prognostic factors for improved overall survival were age 70 years (P=0.03), low and low intermediate IPI (P=0.03), normal WBC (P=0.006), and CR on first line therapy (P 0.001, Table 3 ). Among these prognostic factors, IPI score and complete response to chemotherapy were the most important factors 
DISCUSSION
The proportion of NHL is increasing in elderly people due to the increase of incidence of NHL in older age and the prolongation of life expectancy. However, optimal treatments of NHL in elderly patients are still controversial and many elderly patients are often excluded from conventional chemotherapy. The limiting factors for chemotherapy are poor performance, associated underlying disease or organ dysfunction, and a higher risk for treatment-related toxicity (2 4).
In the Southwest Oncology Group study (2), the treatment outcome in patients with advanced diffuse large cell lymphoma showed that the CR rate after a CHOP regimen was 37% in patients older than 65 years as compared with 65% in patients under 40 years; the survival rate also decreased significantly in older patients. Nonetheless, elderly patients given full doses of the CHOP regimen produced a CR rate similar to that of younger cases. The study suggested that the initial dose reduction for patients aged 65 or older may have contributed to their inferior outcomes. Vose et al (5) treated 112 aggressive NHL patients greater than 60 years with a CAP/BOP regimen (cyclophosphamide, adriamycin, procarbazine, bleomycin, vincristine, prednisone). Although the 5-year survival rate decreased significantly in older patients as compared to those in younger patients (34% vs 62%), there was no significant difference in the complete remission rate between those older or younger than 60 years. In our study, complete remission was achieved in 57.1% of patients, a rate similar to previously reported data supporting the proposition that aggressive NHL in elderly patients is not significantly less responsive than in younger patients.
We found that the independent prognostic factors for improved overall survival were age 70 years, low or low intermediate IPI, normal WBC, and CR on first line therapy. The prognostic role of age has been investigated in many studies and recent multivariate analysis has indicated that age older than 60 years was identified as an important poor prognostic factor for survival in aggressive NHL (6). When we analyzed the prognostic factors considering age in the two groups ( 70 vs 70), older than 70 years of age revealed poor survival suggesting chronological age greater than 70 years might be an independent factor. It has been well recognized that IPI and age-adjusted IPI are significantly accurate in predicting long-term survival (6) . Our results also demonstrated that among the various prognostic factors examined by multivariate analysis, IPI revealed the most important prognostic factor affecting overall survival (odd ratio: 14.84).
Since the achievement of a complete response is a clue for curing lymphoma, several studies have reported that CR is the most significant parameter affecting survival (7, 8) . Our results confirm previous reports that CR to initial first line chemotherapy is an independent prognostic factor affecting survival (odds ratio: 10.39). The International non-Hodgkin's Lymphoma Prognostic Factors Project (6) reported that the factors affecting CR rate included age, stage, site of involvement, size of tumor, performance, serum LDH, albumin, 2-microglobulin level, and B symptoms. However, our study did not show any significant factor that influenced the achievement of CR. This contradictory result may be due to the small number of patients included in our study.
Because elderly patients may have a reduced tolerance for conventional chemotherapy, a number of new combination chemotherapy regimens have been designed for proper management of elderly patients with aggressive NHL (9 11). A prospective, randomized, multicenter phase III trial by Sonneveld et al (12) , comparing the efficacy and toxicity of CHOP versus CNOP (doxorubicin was replaced by mitoxantrone 10 mg/m 2 given intravenously on day 1), showed that CR rates were 49% and 31% in CHOP-and CNOP-treated patients, respectively (P=0.03), and that the overall survival of patients treated with CHOP (median 26 months) was significantly better than with CNOP (median 12 months). This study suggested that CHOP was well tolerated in elderly patients with advanced NHL and toxicity was not an important cause of treatment failures.
Recently, the promising agent rituximab has been developed and investigated for the treatment of low-grade and aggressive lymphoma, particularly in elderly patients, due to its low toxicity. Rituximab is a chimeric murine/human monoclonal antibody that reacts specifically with the B-cell antigen CD20. This agent induced an objective response in approximately 50% of patients with relapsed or chemoresistant low-grade or follicular B-cell lymphoma (13, 14) and also demonstrated significant activity in patients with aggressive NHL. Coiffier et al (15) evaluated the efficacy and the safety of rituximab in patients with relapsed or refractory aggressive NHL and elderly (age 60 years) patients without any prior therapy. The overall response rate was 31% and the median time to progression exceeded 246 days for the responding patients, indicating that rituximab therapy as a single agent has significant antilymphoma activity with a low toxicity in aggressive NHL patients. Vose et al (16) also demonstrated the feasibility and safety of the addition of rituximab to CHOP in the treatment of aggressive B-cell lymphoma. In the United States, a large cooperative group study has an ongoing trial randomizing previously untreated elderly patients with aggressive NHL to either CHOP alone or the rituximab-CHOP combination.
CONCLUSIONS
Our results suggest that even elderly patients with aggressive NHL can be successfully treated with conventional chemotherapy, and in particular, that elderly patients with good prognostic factors should be encouraged to receive chemotherapy. Further clinical trials are required to determine the optimal approach to the management of elderly patients with aggressive NHL.
